Imipenem/Cilastatin is manufactured by Merck and is used to treat bacterial infections. ## Compulsory licenses Compulsory licenses have been issued for Imipenem/Cilastatin in the following instance: ### Italy issued on June 01, 2005 [[Italy]]'s provisions on compulsory licences can be in the Intellectual Property Code. There are two possibilities to obtain a compulsory licence, all regulated by the IP Code: - due to lack of exploitation (Art. 70 IPC); - due to dependent patent (Art. 71 IPC, and Art. 81octies IPC regarding biotech and plant varieties pursuant to the implementation of the Biotech Directive). More information can be found [here](https://e-courses.epo.org/wbts_int/CompulsoryLicensing/CL_IT.pdf). ## Other products issued by the same manufacturer [[EFV]] [[Finasteride]] [[Etoricoxib]] [[Imipenem/Cilastatin]] ## Other products for the same disease